Moreover, the authors demonstrated that down-regulation or inhibition of EZH2 in tumor-specific T cells increases the tumor burden and the metastatic potential in mouse models of ovarian cancer and melanoma, respectively. This evidence concerns the gene EZH2 and ovarian cancer.